Education
About Us
Working with TipRanks
Follow Us
Star Combo Pharma Ltd. (AU:S66)
ASX:S66
S66 Stock Chart & Stats
AU$0.25
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.25
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume100.00K
Average Volume (3M)6.77K
Market Cap
AU$27.00M
Enterprise ValueAU$25.99M
Total Cash (Recent Filing)AU$18.11M
Total Debt (Recent Filing)AU$3.93M
Price to Earnings (P/E)5.1
Beta-0.32
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)0.04
Shares Outstanding135,002,980
10 Day Avg. Volume4,300
30 Day Avg. Volume6,768
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.63
Price to Sales (P/S)0.86
P/FCF Ratio2.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationVery strong free cash flow expansion and a 2.04 OCF-to-net-income ratio indicate durable cash conversion. Over the next 2–6 months this underpins reinvestment, dividend capacity, debt servicing and optional M&A without needing external financing, strengthening operational resilience.
Low Leverage / Balance Sheet StrengthA conservatively leveraged balance sheet (D/E ~0.10) provides long-term financial flexibility and lower solvency risk. This supports steady investment in the business, cushions against revenue volatility, and reduces refinancing pressure across various economic scenarios.
Improving Profitability MetricsMarked improvements in gross and net margins signal better cost control or favorable product mix, enhancing sustainable earnings power. If maintained, higher margins support ROE expansion and funding for growth initiatives, even if top-line growth is uneven in the near term.
Bears Say
Revenue DeclineA contraction in revenue is structurally concerning because it pressures scale economics, limits pricing power and can erode market share. Sustained top-line weakness would force tougher cost cuts or capex reductions, constraining long-term growth and leverage of fixed costs.
Negative EBIT MarginA negative EBIT margin shows core operations are not consistently profitable before financing and tax. This structural inefficiency risks sustainability of earnings improvements and means the company may rely on non-operating items or one-offs to report net profits.
Earnings VolatilityExtremely large EPS swing implies earnings are volatile or driven by one-off events and low comparables. Such volatility reduces visibility for forecasting and capital allocation, increasing execution risk and making it harder to rely on recent earnings as a baseline for medium-term planning.
Star Combo Pharma Ltd. News
S66 FAQ
What was Star Combo Pharma Ltd.’s price range in the past 12 months?
Star Combo Pharma Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Star Combo Pharma Ltd.’s market cap?
Star Combo Pharma Ltd.’s market cap is AU$27.00M.
When is Star Combo Pharma Ltd.’s upcoming earnings report date?
Star Combo Pharma Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 12 days.
How were Star Combo Pharma Ltd.’s earnings last quarter?
Star Combo Pharma Ltd. released its earnings results on Aug 26, 2025. The company reported AU$0.037 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.037.
Is Star Combo Pharma Ltd. overvalued?
According to Wall Street analysts Star Combo Pharma Ltd.’s price is currently Overvalued.
Does Star Combo Pharma Ltd. pay dividends?
Star Combo Pharma Ltd. pays a Notavailable dividend of AU$0.004 which represents an annual dividend yield of 1.54%. See more information on Star Combo Pharma Ltd. dividends here
What is Star Combo Pharma Ltd.’s EPS estimate?
Star Combo Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Star Combo Pharma Ltd. have?
Star Combo Pharma Ltd. has 135,002,980 shares outstanding.
What happened to Star Combo Pharma Ltd.’s price movement after its last earnings report?
Star Combo Pharma Ltd. reported an EPS of AU$0.037 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 18.75%.
Which hedge fund is a major shareholder of Star Combo Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:S66
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Star Combo Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.20%
12-Months-Change
Fundamentals
Return on Equity
14.70%
Trailing 12-Months
Asset Growth
13.16%
Trailing 12-Months
Company Description
Star Combo Pharma Ltd.
Star Combo Pharma Limited engages in the manufacturing and distribution of health food products and nutritional supplements in Australia and China. The company operates in two segments, Star Combo and Austoyou Retail. It develops, manufactures, markets, and sells natural health supplements and skin care products. The company provides its products through e-commerce platform to Chinese health product consumers; and two retail stores in Sydney. Star Combo Pharma Limited was founded in 2004 and is based in Smithfield, Australia.
Technical Analysis
Zoono Group Limited
―
Nanollose Ltd.
―
Skin Elements Limited
―
Lumos Diagnostics Holdings Ltd.
―
―